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Abstract
Despite the wide use of cell lines in cancer research, the extent to which their surface properties correspond to those of
primary tumors is poorly characterized. The present study addresses this problem from a transcriptional standpoint,
analyzing the expression of membrane protein genes - the Membranome – in primary tumors and immortalized in-vitro
cultured tumor cells. 409 human samples, deriving from ten independent studies, were analyzed. These comprise normal
tissues, primary tumors and tumor derived cell lines deriving from eight different tissues: brain, breast, colon, kidney,
leukemia, lung, melanoma, and ovary. We demonstrated that the Membranome has greater power than the remainder of
the transcriptome when used as input for the automatic classification of tumor samples. This feature is maintained in tumor
derived cell lines. In most cases primary tumors show maximal similarity in Membranome expression with cell lines of same
tissue origin. Differences in Membranome expression between tumors and cell lines were analyzed also at the pathway level
and biological themes were identified that were differentially regulated in the two settings. Moreover, by including normal
samples in the analysis, we quantified the degree to which cell lines retain the Membranome up- and down- regulations
observed in primary tumors with respect to their normal counterparts. We showed that most of the Membranome up-
regulations observed in primary tumors are lost in the in-vitro cultured cells. Conversely, the majority of Membranome genes
down-regulated upon tumor transformation maintain lower expression levels also in the cell lines. This study points towards
a central role of Membranome genes in the definition of the tumor phenotype. The comparative analysis of primary tumors
and cell lines identifies the limits of cell lines as a model for the study of cancer-related processes mediated by the cell
surface. Results presented allow for a more rational use of the cell lines as a model of cancer.
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Introduction
Proteins associated with the cell plasma membranes mediate key
processes such as molecular transport, cell adhesion, interaction
with the extracellular matrix, signal transduction and cell-to-cell
signaling. They have long been recognized to play a crucial role in
the genesis and development of cancer, by mediating complex
interactions between the tumor cells surface and the surrounding
cellular environment [1]. Moreover, this class of proteins is of
special relevance in cancer research as it constitutes the target of
election of monoclonal antibodies based therapies [2]. In fact a
number of monoclonal antibody targeting cell surface proteins
have been approved as therapeutics and have consolidated their
value in the treatment of cancer [3]. Many studies focusing on
cellular processes involving surface properties of cancer cells make
use of model cell lines derived from primary tumors. Examples
are: i) the identification of tumor specific membrane proteins
involved in pathways of adhesion and signaling [4]; ii) the assay of
anticancer drugs and antibodies targeting cell surface proteins [5];
iii) the selection of anti-cancer mAbs from antibody libraries using
the cell lines as target [6]; iv) cell binding assays and immuno-
staining experiments [2]. When using in-vitro cell models to mimic
cancer biology it is important to remember that tumors are
complex and heterogeneous systems. They are composed of
different cell types, interacting with each other, with the
extracellular matrix (ECM) and the surrounding tissue through a
complex network of signaling pathways, all mediated by cell
surface proteins. In contrast, cell lines consist of homogeneous
clonal populations generally lacking interactions with other cell
types and instead interacting with an artificial support. Moreover,
cell adaptation to in-vitro microenvironments involves recalibra-
tions of many pathways involving the cell surface, for example by
genetic and epigenetic alterations [7,8], different post-transcrip-
tional regulation [9] and modified signaling networks [10].
Differences in the composition and the functional activity of the
cell surface of primary tumors frequently result in different
sensitivity to anticancer agents, with cell lines being in general
more sensitive to treatments than primary tumors [5]. For these
reasons we believe that a quantitative and qualitative assessment of
the similarities and differences between the cell surface of primary
tumors and related cell lines is of outstanding importance for a
more efficacious use of the cell lines as an in-vitro cancer model. In
fact, despite their wide use, the extent to which the surface
properties of cell lines actually correspond to those of the
corresponding tumor tissues of origin has been poorly character-
ized. We addressed this question from a transcriptional standpoint,
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expression profiles from ten different studies [8,11–19], all using
the same microarray platform. The data set is composed in total of
409 human samples, including normal, primary tumor samples
and tumor derived cell lines. Eight different tissue origins are
represented: brain, breast, colon, kidney, leukemia, lung, melano-
ma, and ovary. We defined as the Membranome the ensemble of all
human genes coding for proteins integral to or covalently
associated with the plasma membrane. First, we demonstrated
that the Membranome expression data have greater power than the
rest of the transcriptome when used as input for the automatic
classification of tumor samples. This property suggests that most of
the gene expression specificity of tumors of different origins resides
into the genes codifying for cell surface proteins. This feature is
maintained in tumor derived cell lines.
Then we run a systematic comparison between the Membranome
expression in tumor and cell lines, using three different analytical
approaches. The first one is based on the direct comparison of the
Membranome expression values in primary tumors and cell lines,
grouped by tissue of origin. The second focuses on pathways
involving the Membranome and identifies those pathways differen-
tially regulated in tumors and cognate cell lines. The third analysis
quantifies the extent to which cell lines reproduce Membranome up-
or down-regulation observed in primary tumors with respect to
their normal tissue counterparts.
Results
Microarray data
Gene expression data on tumor cell lines, primary tumors and
normal tissues were integrated from ten independent studies, all
based on the Affymetrix HG-U95Av2 array platform (see
Methods) (Table 1). The resulting dataset includes 56 cell lines,
294 tumor samples and 59 normal samples representing a total of
8 different tissue origins: brain, breast, colon, kidney, leukemia,
lung, melanoma and ovary.
Definition of human Membranome genes
We defined as the Membranome the ensemble of all human genes
coding for proteins integral or associated to the plasma membrane.
All human genes reported in the NCBI Gene database were
surveyed using a combined analysis of the available Gene Ontology
annotations [20] and through the Phobius algorithm predicting
trans-membrane domains and signal peptides [21].
The resulting human Membranome comprises 4,329 genes
(about 17% of human genes) encoding for plasma membrane
proteins, neglecting the additional complexity introduced by
alternative splicing events or post-translational modifications. Of
these genes, 1,701 are represented on the Affymetrix HG-U95A2
microarray platform, common to all data sets considered in the
present study (Table S1)
Although the array covers only about 40% of the whole
Membranome (Fig. 1A), the internal representation of all major
functional classes – as defined by Panther [22] - is strictly
maintained (Fisher exact test p-value,0.001) (Fig. 1B). Impor-
tantly, the class of Membranome genes annotated as ‘‘molecular
unclassified’’ is under-represented on the array, reflecting a
positive bias towards well annotated genes in the process of array
design.
Membranome classification power with respect to tissue
origin
Much of the biological specificity of different cell and tissue
types is conferred by specialized subsets of proteins present on the
surface of the cell [23]. A large fraction of these proteins have a
structural role, being linked to the cellular cytoskeleton and
conferring specific morphologies to different cell types; others
mediate the response to external stimulus (e.g. cytokines, growth
factors) and/or the interaction with other cells through a variety of
molecular mechanisms [24]. To quantify - in terms of gene
expression - the contribution of Membranome genes in defining the
tumor type specificity, we run a parallel classification study on
primary tumors and tumor derived cell lines. The classification
power of Membranome and an equally sized, randomly chosen, set of
Not-Membranome genes, was used as input for the automatic
classification of samples with different tumor origin.
The results obtained using classifiers of decreasing size (Fig. 2)
show that the Membranome genes have a significantly lower
misclassification rate - and therefore greater power - in classifying
both tumor samples and cell lines according to their tissue of
origin. Importantly, the analysis also shows that the misclassifica-
tion rates obtained for cell lines are significantly higher than those
for primary tumors. In both primary tumors and cell lines
analyses, the eight tissues of origin analyzed gave rise to
comparable frequencies of misclassification. Therefore the ob-
tained misclassification rates cannot be ascribed to specific tissue
types.
Comparison of Membranome expression profiles in
primary tumors and cell lines
To characterize the degree to which cell lines are representative
of their tumor of origin with respect to Membranome expression, a
systematic comparative analysis was performed. Membranome gene
expression in primary tumors and cell lines were compared using
the Pearson’s correlation as metrics of similarity, as described in
Methods. Correlation values between primary tumors and cell
lines, grouped by tissue of origin, are represented in Fig. 3 as box
plots. With the exception of breast and lung, primary tumors
always showed highest similarity with their cognate cell lines (t-test
p-value,0.01). In particular, brain, leukemia, colon and ovary
were the tissues with the most pronounced correspondence
between tumors and cell lines. For breast and lung tumors the
analysis indicates that not only their cognate cell lines, but also cell
lines of different origins have comparable Membranome expression
similarity.
Table 1. Microarray datasets on NCI60 cell lines, primary
tumors and normal tissues analyzed in this study.
Tissue Cell Lines[
8] Normal tissues Tumor tissues
Brain 6 9[
17,18]2 1 [
15]
Breast 6 - 19 [
19]
Colon 7 9[
14,19]2 1 [
19]
Kidney 8 14[
13]1 1 [
19]
Leukemia 6 - 72[
11]
Lung 9 20[
12] 127[
12]
Melanoma 8 - 9 [
16]
Ovary 6 7[
18,19]1 4 [
19]
Total 56 59 294
All the gene expression measurements were obtained with Affymetrix HG-
U95Av2 arrays.
doi:10.1371/journal.pone.0011742.t001
Membranome Expression Analysis
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primary tumors and cell lines
To better characterize the differences between primary tumors
and cell lines at the cell surface level, an analysis of the Membranome
pathways differentially regulated in the two systems was performed.
For each tumor type, differentially regulated genes in primary
tumors and their cognate cell lines were identified by SAM
(FDR,0.01).The resultinggroupsofup-anddown-regulatedgenes
were analyzed separately by using a gene set enrichment approach
(see Methods). A representative extract of the results is illustrated in
Fig. 4 and 5 (complete results are available in Table S4). Among the
dominant themes up-regulated in primary tumors emerge those
related to the immune response (Fig. 4A). These include ‘‘B-cell, T-
cell and antibody mediated immunity’’, ‘‘antigen presentation’’,
‘‘NFAT in immune response’’, ‘‘immunological synapse forma-
tion’’, ‘‘regulation of T-cell proliferation’’, ‘‘Natural killer cell
mediated immunity’’. Other themes generally up-regulated in
primary tumors are those related to ‘‘cell adhesion’’, ‘‘extracellular
matrix’’, ‘‘signal transduction’’, ‘‘cell-cell communication’’. Also the
‘‘cell differentiation’’ and ‘‘organ development’’ pathways appear
also up-regulated in different tumor types (Fig. 4B).
As expected, more specialized pathways/gene sets are up-
regulated in a more restricted manner. Examples are ‘‘nervous
system development’’ and ‘‘melanoma prognosis’’, specifically up-
regulated respectively in brain and melanoma tumors.
Interestingly, the ‘‘breast cancer mutated kinases’’ gene set –
composed of kinases genetically mutated in primary breast tumors
[25] - appears to be up-regulated only in breast and ovary tumors,
as compared to the corresponding cell lines. Overall, only a limited
number of pathways and gene sets were found to be up-regulated
in cell lines vs primary tumors and conservation of up-regulation
was limited across cell lines of different origin (Fig. 5). Examples
include the ‘‘c-myc transcription factor targets upregulated’’
(brain, leukemia, lung), the ‘‘RAS oncogenic pathway signature’’
(brain, lung, kidney) and the ‘‘G-protein signaling, coupled to
cAMP’’ (‘‘colon, ovary, kidney’’). Of interest is also the up-
regulation of pathways related to drug metabolism such as
‘‘detoxification’’, ‘‘ABC transporter’’ (colon and ovary), ‘‘drug
binding’’ (kidney) and ‘‘response to drugs’’ (ovary).
Membranome tumor deregulated genes in primary
tumors and cell lines
To further investigate on the nature of the similarities and
differences between primary tumors and cell lines in the
Membranome expression we considered also samples of normal
origin in the study. We defined as MTDG (Membranome tumor
deregulated genes), those Membranome genes up- or down-regulated
in either primary tumor or cell line samples, as compared to
normal samples with the same tissue origin. The analysis was
restricted to those tissues for which cell lines, primary tumors and
normal samples were available: brain, lung, colon, ovary and
kidney. For each tissue, MTDG were identified in primary tumors
and cell lines, using SAM (FDR,0.01) [26] (Table 2 and Table S3)
and the percentages of MTDG with consistent regulation between
Figure 1. Definition of the Human Membranome. A) Schematic representation of the strategy used to identify the Human Membranome.
Combining annotations (GO), predictions (Phobius) and manual revision we estimate that approximately 17% of human protein coding genes are
exposed on the plasma membrane on the cell. 39% of them are represented on the Affymetrix HG-U95A/Av2 array. B) Panther Molecular Function
composition of the Membranome. The percentage of genes annotated in each category is shown for the complete set of membranome genes
(purple) and for the fraction that is represented on the array (blue).
doi:10.1371/journal.pone.0011742.g001
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Fig. 6). The highest match was observed in brain, ovary and lung
tissues, with 65%, 65% and 64%, respectively, of common MTDG
between primary tumors and cell lines. Ovary, colon and kidney
follow with 44% and 39%, respectively. When the percentages are
instead analyzed separately for up- and down-regulated MTDG,
higher values where consistently obtained for down-regulated
MTDG. A significant portion of Membranome genes up-regulated in
primary tumors therefore lose their de-regulation in cell lines, i.e.
following immortalization and in the context of in-vitro growth
conditions. Conversely, the majority of Membranome genes down-
regulated upon tumor transformation maintain lower expression
levels also in the cell lines. Noteworthy, tumors of different types
always show the most significant overlap with the cell lines of same
tissue origin (Table 3).
Discussion
Characterization of general transcriptional similarities and
differences between cell lines and primary tumors has been
addressed by a variety of studies [27–32]. Higher proliferation rate
and the adherent growth conditions of in-vitro cultured cell-lines
appear to be the major factors clearly differentiating the two
systems [33]. However, despite the crucial role of the cell surface
in the cancer biology, and the common use of cell lines as an
in-vitro model for cancer, little is known on how cell surface
properties change when tumor cells move to in-vitro growth
conditions. Here we examined the problem with a very focused
perspective, specifically looking at genes codifying for plasma
membrane proteins – the Membranome. These genes not only play a
crucial role in the genesis and development of cancer, by
mediating complex interactions between the tumor cells surface
and the surrounding cellular environment [1], but constitute the
target of election of monoclonal antibodies based therapies [2].
First we demonstrated that the expression of Membranome genes
has greater power, as compared to the rest of the transcriptome,
when used for the automatic classification of tumor samples
according to their tissue of origin. This is also true for cell lines,
although they are more difficult to classify and give rise to higher
misclassification rates. These observations reinforce the role of
Figure 2. Classification power of Membranome genes. Classification power of Membranome genes in primary tumors (top panel) and cell lines
(bottom panel). PAM algorithm was applied to compute the misclassification rate of both Membranome and not- Membranome genes using classifiers
of increasing size. Dotted lines represent exponential fits of the data points resulting from the analyses. Membranome genes showed a lower
misclassification rate in classifying both tumor samples and cell lines according to their tissue origin.
doi:10.1371/journal.pone.0011742.g002
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that much of the specificity of tumors originating from different
tissues resides in their cell surface components. The higher
promiscuity of cell lines in classification analysis mirrors - at a
transcriptional level - the notion that in-vitro stabilized tumor cells
have lost the tissue organization - and therefore the membrane
characteristics - of the in-vivo tumor.
In order to quantify the degree to which cell lines are
representative of their tumor of origin, with respect to Membranome
expression, we have run a correlation analysis between primary
tumors and cell lines. We showed that, with the exception of breast
and lung, primary tumors show cell surface maximal similarity
with the cell lines of same tissue origin (t-test p-value,0.01). In
particular, brain, leukemia, colon and ovary were the tumors with
the most pronounced correspondence, suggesting their membrane
composition being mostly preserved in the cognate cell lines. The
lack of maximal correlation between breast and lung cell lines with
their respective tumors can probably be ascribed to their
heterogeneous gene expression patterns, already pointed out by
previous clustering analysis, in this case performed at the whole-
genome level [8].
To understand which cell surface biological themes are
differentially regulated between primary tumors and cell lines, a
gene set enrichment analysis against a large sets of databases and
cancer data extracted from the literature was performed.
This type of analysis is significantly more interpretable than a
standard gene-level approach as it allows for a global overview of
the cell surface processes differentiating the two systems,
potentially hidden from a gene-centric perspective.
With gene set enrichment analysis lists of up- and down-
regulated genes are translated into a more interpretable view of the
biological pathways, which – as wholes - are differentially
regulated in primary tumors and cell lines. Another important
advantage lays in the fact that the perturbation of each pathway is
quantified by an ‘‘aggregated’’ value, inferred from the statistical
integration of dozens of genes taking part to the same pathway.
This makes this analysis intrinsically more resistant to the presence
of false positive/negative genes, which could potentially affect a
‘‘gene-centric’’ analysis, based on the evaluation of individual data
points.
Among the dominant themes up-regulated in primary tumors
emerge those related to the immune response, pathways known to
be up-regulated in all tumors, regardless of their tissue of origin
[27] (Fig. 4A). Tumor infiltrating lymphocytes (TIL) present in the
extracted tumor samples are probably responsible for part of these
molecular phenotypes. However, also pathways related to MHC
class I antigen presentation emerge from the analysis, indicating an
active role of tumor cells in the activation of immune response
pathways and mirroring the complex interplay between tumor
cells and TIL. We also observed the up-regulation of the
‘‘chemotaxis’’ and ‘‘cytokine and chemokine mediated signaling’’
pathways, respectively in five and three tumor types. Taken
together these data are coherent with a recently proposed model of
interaction between tumor and immune system cells [34]. The
model suggests that TIL provide cytokines and growth factors
necessary for tumor growth with tumor cells producing chemo-
tactic factors that actively recruit mononuclear cells, mainly
lymphocytes and macrophages, to tumor sites [34].
Figure 3. Correlation of Membranome gene expression profiles between primary tumors and cell lines. Each boxplot represents the
distribution of correlation coefficients obtained comparing gene expression profiles of cell lines and primary tumors of various tissue origins. The y-
axis represents the Pearson’s correlation coefficients. The origin of the cell lines is labelled on the x-axis. Boxes corresponding to cell lines and primary
tumors with the same tissue origin are labelled in red. Excepted for breast and lung, the primary tumors always showed the highest similarity with
their cognate cell lines (t-test p-value,0.01).
doi:10.1371/journal.pone.0011742.g003
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related to ‘‘cell adhesion’’, ‘‘extracellular matrix’’, ‘‘signal transduc-
tion’’ and ‘‘cell-cell communication’’ (Fig. 4B). The up-regulation of
many genes involved in these pathways apparently reflects the
organization of primary tumor cells in tissues, in contrast to the
altered environment of cells growing in-vitro in defined cell-culture
media [35–37]. The ‘‘cell differentiation’’ and ‘‘organ develop-
ment’’ pathways appear also up-regulated in different tumor types
reflecting a general higher level of differentiation of primary tumor
cells. Additional pathways/gene sets are instead up-regulated in a
more tissue specific manner. Examples are ‘‘nervous system
development’’ and ‘‘melanomaprognosis’’, specifically up-regulated
in brain and melanoma tumors, respectively. Interestingly, although
brain tumors show up-regulation of some immune-related process-
es, many immune related gene sets do not show up. This divergence
from other tumor types can possibly be explained by the particular
characteristicsofthe CNS cellularenvironment,whichinfluences its
receptivity to immune activity. For example the existence of the
blood-brain barrier (BBB), lower T-cell numbers within the CNS
under normal circumstances and unconventional lymphatics [38].
The ‘‘breast cancer mutated kinases’’ gene set – composed of
kinases found to be genetically mutated in primary breast tumors
[25] - was found to be up-regulated only in breast and ovary
tumors, as compared to cell lines. Both these tumors are
originating from estrogen responsive tissues and are known to
share hereditary genetic predisposition factors [39].
Only a limited number of pathways and gene sets were found to
up-regulated in cell lines vs primary tumors. This is consistent with
the results of the Membranome tumor deregulated genes (MTDG)
analysis discussed below, showing that a significant portion of
the Membranome loses its up-regulated state passing from in-vivo to
in-vitro conditions. Noticeably, the gene sets we identified as up-
regulated in cell lines, have limited conservation across cell lines of
different origin (Fig. 5). These include the ‘‘c-myc transcription
factor targets upregulated’’ (brain, leukemia, lung), the ‘‘RAS
oncogenic pathway signature’’ (brain, lung, kidney) and the ‘‘G-
protein signaling, coupled to cAMP’’ (‘‘colon, ovary, kidney’’). The
up-regulation of these pathways is likely to reflect cell-line specific
activation of signal transduction pathways through the cell surface
and are related to the higher proliferation rate of the in-vitro
cultures. Of interest is also the up-regulation of pathways related to
drug metabolism such as ‘‘detoxification’’, ‘‘ABC transporter’’
(colon and ovary), ‘‘drug binding’’ (kidney) and ‘‘response to
drugs’’ (ovary). The differential regulation of these pathways can
possibly underpin the different anticancer drug sensitivities
observed in-vitro and in-vivo [27].
With the analysis of MTDG, we enquired whether Membranome
genes deregulated in primary tumor samples as compared to their
normal tissue counterparts retain their altered state also in the cell
lines. This information is of key importance when using the cell
lines as an in-vitro model for surface cancer targets. Examples are
the screening of anticancer therapeutics targeting cell surface
Figure 4. Gene sets enriched in genes up-regulated in tumors. Heatmap showing the gene sets significantly enriched in Membranome genes
up-regulated in tumors as compared to cell lines of the same tissue origin. A) Immune-related pathways B) Other pathways. Gene set enrichment p-
values, calculated using Fisher-exact test are represented by color codes (see legend).
doi:10.1371/journal.pone.0011742.g004
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cancer specific mAbs from random peptide libraries [6,41].
Importantly, a significant portion of MTDG over-expressed in
primary tumors are lost in cell lines. Conversely, the majority of
MTDG down-regulated upon tumor transformation are retained
in in-vitro cultured cells (Fig. 6). The observation that cell lines tend
to lose the tumor-specific gene up-regulations is in agreement with
what previously reported at global transcriptional level [29].
Another interesting observation is that tumors of different origin
always have the most significant overlap of MTDG with the cell
lines originating from the same tissue (Table 3). This is true even
for lung tumors, where the correlation analysis demonstrated a
high level of similarity also with cell lines other than lung. It
therefore appears that cell lines - despite some loss of the overall
tumor characteristics - preferentially retain the tumor specific
Membranome deregulation observed in primary tumors as compared
to their normal counterparts.
As a further development of this study, the Membranome analysis
at the protein level would be very useful to complement and
validate our observations at the transcriptional level. In fact,
mRNA abundances do not necessarily correspond to the levels of
the protein functionally available and expressed on the cell surface.
However, while recognizing the importance of this information for
the detailed dissection of individual pathways, we believe the
statistical approach that was undertaken in our study guarantees
the general observations and conclusions to be valid also at the
Figure 5. Gene sets enriched in genes down-regulated in tumors. Heatmap showing the gene sets significantly enriched in Membranome
genes down-regulated in tumors as compared to cell lines of the same tissue origin. Gene set enrichment p-values, calculated using Fisher-exact test
are represented by color codes (see legend).
doi:10.1371/journal.pone.0011742.g005
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divergences (high mRNA-low protein and vice-versa) can exist,
their effects are expected to reciprocally compensate – and
therefore to be strongly mitigated – in the context of a ‘‘global’’
scale analysis, one involving thousands of genes.
Additional comments need to be made regarding the samples
we considered in the analysis. Our study has been constrained by
the availability of transcriptional data sets publically available on a
coherent microarray platform (the integration of data sets deriving
from different technologies would have introduced too much noise
in the meta-analysis). As a result, we created a meta-dataset, all
based on the Affymetrix HG-U95Av2 platform, which to our
knowledge was the platform covering the broadest spectrum of
tumor samples. It encompasses 10 independent studies, covering a
total of 409 human samples deriving from 8 different tissues.
Additional tumors (e.g. sarcoma tumors, because of their
particular biology involving the interactions with the extracellular
matrix) and in-vitro tumor models (e.g. cell lines grown in three-
dimensional conditions such as mammospheres or neuroshperes) could
add further interest to our observations.
Using transcriptional data from a large set of primary tumors,
normal tissue and cell lines of different origin we have
demonstrated a central role of Membranome genes in characterizing
the tumor phenotype. The comparative analysis of primary tumors
and corresponding cell lines reemphasizes the caution that should
applied when using these model systems in the study of the cancer.
The presented results contribute to a more informed use of cell
lines and interpretation of results with regards to specific aspects of
tumor biology involving the cell surface.
Materials and Methods
Microarray data
Expression data for NCI60 cell lines were made publicly
available through the Developmental Therapeutics Program of
NCI/NIH. The NCI60 dataset includes data from 59 cell line.
Cell culture growth conditions are described in [8]. The two cell
lines of prostate origin (PC3 and DU-145 [8]) were not included
because previous studies showed a low correlation with primary
prostate tumors [30] as well as with other tumors [29]. We further
Figure 6. Membranome Tumor Deregulated Genes in tumors and cell lines. Percentages of the Membranome Tumor Deregulated Genes
(MTDG) consistently deregulated in primary tumors and cell lines with the same origin. The number of MTDG in tumors and cell lines is reported in
Table 2.
doi:10.1371/journal.pone.0011742.g006
Table 2. Membranome differentially regulated genes (MTDG) in primary tumors and cell lines.
Data Brain Lung Colon Ovary Kidney
Cell lines UP 353 183 48 334 179
Cell lines DOWN 528 503 311 363 418
Tumor tissue UP 363 158 76 193 273
Tumor tissue DOWN 277 366 227 207 355
Intersection: cell lines and tumor tissue UP 199(55%) 60(38%) 12(16%) 111(58%) 78(29%)
Intersection: cell lines and tumor tissue DOWN 217(78%) 277(76%) 122(54%) 148(71%) 169(48%)
Intersection: cell lines and tumor tissue UP or Down 416(65%) 337(64%) 134(44%) 259(65%) 247(39%)
The percentages of MTDG identified in primary tumors showing coherent regulation in the cell lines are shown in parentheses.
doi:10.1371/journal.pone.0011742.t002
Membranome Expression Analysis
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classification: originally considered as breast, it has also been
reported to originate from melanoma [8,29,42].
No specific information is reported in the existing literature
regarding the cell passage number at which cell lines were
processed for microarray analysis. However, interesting informa-
tion regarding this point can be found in the work of Ross and
collaborators: ‘‘[…]RNA samples from two cell lines (MCF7 breast and
K562 leukaemia) were collected on three different occasions (at different
passage numbers), then labelled, hybridized and scanned independently. These
replicates (labeled MCF7 I, II and III, and K562 I, II and III) clustered side
by side, with approximately the same degree of similarity as shown by the
MDA-MB435/MDA-N pair […]’’ [8].
These data, although limited to two cell lines only, point
towards a relative transcriptional stability of these cell line samples
across different passage numbers.
The set of primary tumors included 21 classic glioblastoma and
anaplastic oligodendroglioma [15], 19 infiltrating ductal breast
adenocarcinomas [19], 21 colorectal adenocarcinomas [19], 11
clear cell carcinoma of the kidney [19], 14 serous papillary ovarian
adenocarcinomas [19], 72 leukemia samples (including 20 mixed-
lineage leukemias, 24 acute lymphoblastic leukemias and 28 acute
myelogenous leukemias) [11], 127 lung adenocarcinomas [12] and
9 melanoma tumors [16].
Normal tissue samples data were available for five different tissue
types: brain [17,18], colon [14,19], kidney [13,17–19], lung [12,19]
and ovary [18,19]. All data are MIAME compliant and the raw data
have been deposited in a MIAME compliant database. Expression
data can be obtained from the following sources: [8], Developmental
Therapeutics Program of NCI/NIH at http://dtp.nci.nih.gov/
mtargets/download.html; [11,12,15], supplementary material
available at http://www.broadinstitute.org/cgi-bin/cancer/datasets.
cgi; [13], GEO accession GSE1563; [14], GEO accession GSE405;
[16], supplementary material available at http://www.mskcc.org/
genomic/ccsmsp/; [17], GEO accession GSE803; [18], GEO
accession GSE96; [19], supplementary material available at http://
public.gnf.org/cancer/epican/.
The meta-dataset deriving from the integration of the individual
data sets described above represent to our knowledge the largest
study publicly available based on the Affymetrix HG-U95Av2
array. More detailed information on samples included in this study
is provided in Table S2.
Data processing
All datasets were processed using the MAS5 algorithm
implemented in R [43] and scaled to a trimmed mean value of
500. Expression values across technical replicates were averaged
for lung tumors, brain normal, kidney normal and ovary normal
samples. All arrays were normalized using a quantile normaliza-
tion algorithm [44]. Finally, data was log 2 transformed prior to
analysis.
Classification of Membranome genes
A semi-automated procedure was applied to identify the human
Membranome, here defined as the ensemble of all human genes
coding for proteins integral to or covalently associated with the
plasma membrane,
All human genes reported in the NCBI CCDS database (NCBI
Build 37.1) [45–46] were surveyed using a combined analysis of
the available Gene Ontology annotations [20] and the results of
the Phobius algorithm for the prediction of trans-membrane
domains and signal peptides [21]. The list of membrane protein
genes thus created was manually revised to exclude proteins
localized in intracellular compartments (false positives) and to
include additional membrane-associated proteins known from
literature (false negatives). These proteins were initially not
included by the automated analysis because of missing annotation
and/or lack of transmembrane domains, for example GPI–
anchored proteins.
Classification Analysis
To compute the ‘discriminative power’ of Membranome and Not-
Membranome genes the PAM method (‘‘Prediction Analysis of
Microarrays’’, PAM) [47] was applied to classify samples
according to their tissue of origin.
PAM is based on nearest shrunken centroids classification and
builds a classifier by identifying those genes that best characterize
each group of samples. The size of the gene list used as the
classifier, and the corresponding misclassification rate, depend on
the shrinkage parameter D provided as input. PAM was run
independently on primary tumors and cell lines using gene lists of
decreasing sizes. Parallel analyses were performed using equally
sized lists of Membranome and Not-Membranome genes, randomly
chosen. For each list size (and therefore for each value of D) the
analysis was run 1.000 times and the results of misclassification
were averaged.
Correlation analysis of cell lines and primary tumors
Cell lines and primary tumors were grouped according to their
origin: brain, leukemia, lung, melanoma, breast, colon, ovary and
kidney. All possible pairs of tumor and cell line samples were
compared using the Pearson’s correlation coefficient as the metric
of similarity. Pearson’s correlation values were computed between
all tumor samples and all cell lines of two given groups (e.g. all lung
tumors vs all breast cell lines). The resulting distributions of
correlation values were represented as a box plots in Fig. 3. Mean
values of correlation distributions were compared by Student’s
t-test with Bonferroni multiple comparison correction.
Differential expression of Membranome genes
For each of the eight tissues in analysis, we computed the list of
Membranome genes up- and down-regulated in the primary tumors
as compared to the corresponding cell line, with the same tumor
tissue origin (Table S3). For the five tissues for which also the
normal samples were available (brain, colon, kidney, lung, ovary),
we identified the MTDG (Membranome tumor deregulated genes)
defined as Membranome genes up- or down-regulated in primary
tumors or cell lines as compared to the normal samples of same
tissue origin. Gene up- and down-regulations were in all cases
assessed using the significance analysis of microarrays (SAM) [26],
Table 3. 2log10 Fisher exact test p-values of the overlaps
between MTDG in primary tumors (T) and cell lines (CL).
Brain (T) Lung (T) Colon (T) Ovary (T) Kidney (T)
Brain (CL) 23.5 0.0 0.0 0.0 0.0
Lung (CL) 0.0 40.6 2.8 0.0 0.0
Colon (CL) 0.0 8.8 23.8 0.0 0.0
Ovary (CL) 0.0 2.6 0.0 30.3 0.0
Kidney (CL) 0.0 0.2 0.1 0.0 3.2
The table shows that all the primary tumors analyzed have the highest
statistically significant overlap with the cell lines originating from the same
tumor type.
doi:10.1371/journal.pone.0011742.t003
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FDR,0.01 for each pair wise comparison. For each tissue type,
two lists of MTDG were compiled, respectively from the Tumor vs
Normal and Cell line vs Normal comparisons.
The significance of the overlap between pairs of the lists was
computed by using the Fisher’s exact test and are reported in
Table 3 as the negative log10 of the p-value obtained.
Gene Set Enrichment Analysis
Lists of genes differentially up- or down- regulated were
compared to annotated gene sets in order to identify functional
classes that are significantly over-represented. Enrichment p-values
were computed according to the Fisher’s exact test. Gene sets were
obtained from publicly publically available sources (Gene
Ontology [20], KEGG [48], InterPro [49], Panther [22],
Swissprot keywords, chromosome localization, miRNA targets
identified after miRNA transfection [50], gene sets of relevance for
cancer taken from several published sources [51–60]) and
additional sources (GeneGo (GeneGo Inc., St Joseph, MI, USA),
Ingenuity (Ingenuity Systems Inc, Mountain View, CA, USA),
TRANSFAC [61]).
We decided to use and report the uncorrected p-values and not to
correct for multiple testing. The latter decision was based on the
observation of a very high degree of overlap between different
gene sets. As a consequence, single tests performed on the
individual gene sets are strongly dependent on each other,
violating the assumption of independence required by standard
correction methods such as ‘Bonferroni’, ‘Holm’ and ‘FDR’. Thus,
in this context, standard correction for multiple testing would have
resulted as too conservative. To be noted also that most of the
pathways discussed have a p-value much lower than the standard
threshold of 0.01.
Supporting Information
Table S1 List of the 4,329 Human Membranome genes. Gene
identifiers are based on the NCBI Build 37.1.
Found at: doi:10.1371/journal.pone.0011742.s001 (0.56 MB
XLS)
Table S2 Detailed description of the 409 samples analyzed in
this study.
Found at: doi:10.1371/journal.pone.0011742.s002 (0.10 MB
XLS)
Table S3 Results of differential expression analysis (SAM,
FDR,0.01). The file contains the complete list of 2,247
Affymetrix probes mapping to 1,701 Membranome genes represent-
ed on the HG-U95Av2 array. For each probe the table shows
(from left to right): Affymetrix ID; Entrez GeneID; whether the
probe is differentially expressed (SAM, FDR,0.01) in tumor-to-
cell line, tumor-to-normal and cell line-to-normal comparisons;
whether the probe is consistently differentially expressed in tumor-
to-normal and tumor-to cell line comparisons. CL: cell line, T:
primary tumor, N: normal sample.
Found at: doi:10.1371/journal.pone.0011742.s003 (1.62 MB
XLS)
Table S4 Results of gene set enrichment analysis. The file
includes the 639 gene sets significantly enriched (p,0.05) in at
least one of the comparisons tumor-to-cell line, tumor-to-normal
and cell line-to-normal. For each gene set the table shows (from
left to right): gene set ID; source of the gene set; gene set name; p-
value enrichment (Fisher’s exact test) for the genes differentially
expressed (SAM, FDR,0.01) in each comparison; the number of
overlapping genes; the Entrez Gene IDs of the overlapping genes.
CL: cell line, T: primary tumor, N: normal sample.
Found at: doi:10.1371/journal.pone.0011742.s004 (1.96 MB
XLS)
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